Evidence map›Paper›PMID 32282861›Full record

ArticlePloS one2020

Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients.

Nir Hirshoren, Roni Yoeli, Jonathan E Cohen, Jeffrey M Weinberger, Nadia Kaplan, Sharon Merims, Tamar Peretz, Michal Lotem

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nir HirshorenDepartment of Otolaryngology / Head & Neck Surgery, Hadassah Hebrew-University Medical Center, Jerusalem, Israel.ORCID 0000-0002-5601-8336
Roni YoeliDepartment of Otolaryngology / Head & Neck Surgery, Hadassah Hebrew-University Medical Center, Jerusalem, Israel.
Jonathan E CohenSharett Institute of Oncology, Hadassah Hebrew-University Medical Center, Jerusalem, Israel.
Jeffrey M WeinbergerDepartment of Otolaryngology / Head & Neck Surgery, Hadassah Hebrew-University Medical Center, Jerusalem, Israel.
Nadia KaplanRadiology department, Hadassah Hebrew-University Medical Center, Jerusalem, Israel.
Sharon MerimsSharett Institute of Oncology, Hadassah Hebrew-University Medical Center, Jerusalem, Israel.
Tamar PeretzSharett Institute of Oncology, Hadassah Hebrew-University Medical Center, Jerusalem, Israel.
Michal LotemSharett Institute of Oncology, Hadassah Hebrew-University Medical Center, Jerusalem, Israel.
Hadassah Medical Center · ILHebrew University of Jerusalem · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to investigate if the treatment outcomes of checkpoint inhibitors (CPI) in patients with advanced-stage skin head and neck melanoma (HNM) differs from outcomes in patients with non-HNM.

designA retrospective cohort study of patients with unresectable AJCC stage III and stage IV, who received CPI between 2010 and 2017.

participantsOverall, 122 unresectable AJCC stage III and metastatic stage IV melanoma adult patients were treated with CPI during the study period (consecutive patients). The HNM group of patients was comparable with limbs and trunk melanoma group except different distant metastatic (M1a/b/c/d) pattern (p = 0.025). MAIN OUTCOMES: Comparison of overall survival and clinical response to CPI in patients with advanced-stage skin melanoma of the head and neck with non-HNM.

resultsWe analyzed 38 patients with melanoma arising in the head and neck skin regions, 33 with melanoma of limbs and 51 with trunk melanoma. Most of the head and neck patients were men (89.5%), the average age of melanoma diagnosis was 61.4±16.7 years (range 16.4-85.6). More than a third of HNM group of patients (36.8%) were 70 years and older. Overall response rate (ORR) to CPI was 50% (CR 31.6% and PR 18.4%) in the head and neck study group of patients, compared to an ORR of 36.3% and 23.5% in melanoma of the limbs and of the trunk, respectively (p = 0.03). The median overall survival of HNM group of patients was 60.2±6.3 months, CI 95% [47.7-72.7], 63% were alive at 30 months, reaching a plateau. Whereas, the median survival time of limbs and trunk melanoma were 51.2 and 53.4 months, which did not reach significance. CONCLUSIONS AND RELEVANCE: Response rate to CPI is significantly improved in patients with melanoma of the head and neck and they have a trend towards improved, long standing, overall survival.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalCTLA-4 AntigenFemaleHead and Neck NeoplasmsHumansIpilimumabMaleMelanomaMiddle AgedProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin NeoplasmsAntineoplastic Agents, ImmunologicalCTLA-4 AntigenCTLA4 protein, humanIpilimumabPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID32282861
PMCPMC7153888
OpenAlexW3015402578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.